Anti-Spot, Lightening Effect and Cutaneous Acceptability of a Stable Anhydrous Ecobiological Formulation of 10% L-Ascorbic Acid

Elise Abric,Jessica Mathias,Anne-Sophie Tardieu,Léa Mateos,Chantal Eeckhout,Fanny Drulhon,Nathalie Ardiet
DOI: https://doi.org/10.2147/ccid.s443182
2024-02-29
Clinical Cosmetic and Investigational Dermatology
Abstract:Elise Abric, Jessica Mathias, Anne-Sophie Tardieu, Léa Mateos, Chantal Eeckhout, Fanny Drulhon, Nathalie Ardiet Research and Development Department, NAOS Ecobiology Company (Bioderma - Institut Esthederm - Etat Pur), Aix-en-Provence, France Correspondence: Léa Mateos, NAOS Ecobiology Company (Bioderma - Institut Esthederm - Etat Pur), Research and Development Department, Aix-en-Provence, France, Email Vitamin C or L-ascorbic acid (AA), its most biologically active form, is the most abundant antioxidant in healthy skin. Vitamin C is well-known for its anti-aging skin effects, like the inhibition of skin damage by free radicals, stimulation of collagen biosynthesis, inhibition of melanogenesis, and improvement of various inflammatory skin disorders. 1 Thus, vitamin C is widely used in skin care products. However, vitamin C is highly unstable in aqueous solution, in the presence of oxygen and metal ions. Its oxidation is associated with a yellowish coloration of the formulation and loss of biochemical properties. AA stability in cosmetics remains a challenge despite several strategies, like the reduction of water content, the addition of antioxidants, the encapsulation in micro or nanoparticles, the use of more stable derivatives of vitamin C or multiple phase emulsions. 2 To address this problem, an anhydrous formulation was developed, consisting of pure AA (10%) dissolved in two natural polyols compounds, propanediol and glycerin – a naturally occurring molecule of the skin. The anhydrous formulation stored in glass vials and white bottles remained colorless with a perfect stability of AA for 24 months at room temperature protected from light. Few clinical studies reported the efficacy of topical application of vitamin C alone or its derivatives on hyperpigmentation disorders caused by exposure to UV radiations (photoaging). 3,4 AA decreases UVA-induced melanogenesis through its antioxidant properties 5 and may interfere with tyrosinase action, the main enzyme involved in melanin synthesis. 1 A clinical study was conducted to assess the anti-spot/lightening effect and the acceptability of the new product. This clinical study complied with the Declaration of Helsinki, Good Clinical Practice Guidelines, and local laws and regulations. The European Directive 2001/20/EC and regulations issued by the Minister of Health (Order of the Minister of Health of May 2, 2012 regarding Good Clinical Practice, Dz.U. 2012, item 491) was not applicable. Therefore, this study was considered as non-interventional and did not require the Ethics Committee Approval and the Competent Authority Authorization. All the subjects provided written informed consent prior to their participation in the study. Thirty-three healthy women, aged between 33 and 64 years, with sensitive skin, phototype I to III, and at least 1 pigmentary spot (lentigo > 3 mm) on the face were enrolled at the end of October 2020. Thirty-one subjects completed the study. They applied twice daily for 2 months 1 drop of the product on each cheek and on the forehead, then massaged until completely absorbed. Two zones were defined on the face, one with pigmentary spot and one with normal pigmentation, for color measurements using a Konica Minolta CM700-d spectrophotometer equipped with a 3 mm diameter head. The parameters L* (luminance) and b* (cutaneous melanin yellow color) were recorded on day 0 (baseline) (D0), then 28 (D28) and 56 days (D56) after product application. The Individual Typological Angle (ITA°) was calculated from the L* and b* parameters, ITA° being inversely related to pigmentation. The cutaneous acceptability of the product was assessed through an evaluation questionnaire on D56. L* and ITA° mean values increased on D28 and D56 on the pigmented area, reaching values close to those recorded on the "normal" skin area, where both parameters remained stable (Figure 1). The increase from baseline of both parameters was significantly higher on D28 and D56 on the pigmented skin area than on the "normal" skin. Lighter (L* parameter) and less pigmented spots (ITA° parameter) were obtained on D56 in 93% and 90% of subjects, respectively. The product was very well tolerated (only one subject presented mild burning sensation after the product application from D8 to D32 judged as not relevant by the investigator), assessed as pleasant by 84% of women, with a visible improvement of the skin (Figure 2). Figure 1 Evolution of the L* (skin lightness) ( A ) and ITA° (skin pigmentation degree) ( B ) parameters. Mean values ± SEM of the L* ( A ) and ITA° ( B ) parameters on the pigmented and normal skin zones were recorded after twice daily application of the product for 28 (D28) and 56 days (D56). Three measurements were made using a spectrophotometer per zone -Abstract Truncated-
dermatology
What problem does this paper attempt to address?